Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Operations (2019 - 2025)

aTYR PHARMA's Cash from Operations history spans 7 years, with the latest figure at 12196000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 7.13% year-over-year to 12196000.0; the TTM value through Dec 2025 reached 61986000.0, up 10.32%, while the annual FY2025 figure was 61986000.0, 10.32% up from the prior year.
  • Cash from Operations reached 12196000.0 in Q4 2025 per ATYR's latest filing, up from 20476000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 590000.0 in Q1 2023 to a low of 22380000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 11964350.0, with a median of 11740000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: surged 94.17% in 2023, then crashed 3693.22% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 8086000.0 in 2021, then decreased by 28.23% to 10369000.0 in 2022, then dropped by 6.68% to 11062000.0 in 2023, then dropped by 18.71% to 13132000.0 in 2024, then rose by 7.13% to 12196000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Cash from Operations are 12196000.0 (Q4 2025), 20476000.0 (Q3 2025), and 13894000.0 (Q2 2025).